Evidence map›Paper›PMID 27637082›Full record

ArticleOncotarget2016

Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Angela Diana, Lai Mun Wang, Zenobia D'Costa, Abul Azad, Michael A Silva, Zahir Soonawalla, Paul Allen, Stanley Liu, W Gillies McKenna, Ruth J Muschel and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Brachytherapy via a depot of biopolymer-boundNature biomedical engineering · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Oncotarget · 2017
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Angela DianaDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Lai Mun WangDepartment of Pathology, Oxford University Hospital NHS Foundation Trust, Oxford, UK.
Zenobia D'CostaDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Abul AzadDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Michael A SilvaDepartment of Surgery, Oxford University Hospital NHS Foundation Trust, Oxford, UK.
Zahir SoonawallaDepartment of Surgery, Oxford University Hospital NHS Foundation Trust, Oxford, UK.
Paul AllenDepartment of Pathology, Oxford University Hospital NHS Foundation Trust, Oxford, UK.
Stanley LiuDepartment of Radiation Oncology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
W Gillies McKennaDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Ruth J MuschelDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Emmanouil FokasDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
University of Oxford · GBCRUK/MRC Oxford Institute for Radiation Oncology · GBOxford Health NHS Foundation Trust · GBHealth Sciences Centre · CA

Funding

Cancer Research UK 20407Medical Research Council MC_PC_12004
6 · The paper itself

Abstract

We assessed the prognostic value of hypoxia (carbonic anhydrase 9; CA9), vessel density (CD31), with macrophages (CD68) and B cells (CD20) that can interact and lead to immune suppression and disease progression using scanning and histological mapping of whole-mount FFPE pancreatectomy tissue sections from 141 primarily resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with surgery and adjuvant chemotherapy. Their expression was correlated with clinicopathological characteristics, and overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), also in the context of stroma density (haematoxylin-eosin) and activity (alpha-smooth muscle actin). The median OS was 21 months after a mean follow-up of 20 months (range, 2-69 months). The median tumor surface area positive for CA9 and CD31 was 7.8% and 8.1%, respectively. Although total expression of these markers lacked prognostic value in the entire cohort, nevertheless, high tumor compartment CD68 expression correlated with worse PFS (p = 0.033) and DMFS (p = 0.047). Also, high CD31 expression predicted for worse OS (p = 0.004), PFS (p = 0.008), LPFS (p = 0.014) and DMFS (p = 0.004) in patients with moderate density stroma. High stromal and peripheral compartment CD68 expression predicted for significantly worse outcome in patients with loose and moderate stroma density, respectively. Altogether, in contrast to the current notion, hypoxia levels in PDAC appear to be comparable to other malignancies. CD31 and CD68 constitute prognostic markers in patient subgroups that vary according to tumor compartment and stromal density. Our study provides important insight on the pathophysiology of PDAC and should be exploited for future treatments.

Indexed as

AgedAged, 80 and overAntigens, CDAntigens, CD20Antigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorCarbonic Anhydrase IXCarcinoma, Pancreatic DuctalCD68 MoleculeCombined Modality TherapyFemaleHumansHypoxiaImmunohistochemistryMacrophagesAntigens, CDAntigens, CD20Antigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorCA9 protein, humanCarbonic Anhydrase IXCD68 antigen, humanCD68 MoleculePlatelet Endothelial Cell Adhesion Molecule-1desmoplastic stromahypoxiamacrophagesprognosisvessel density

Identifiers

PMID27637082
PMCPMC5341946
OpenAlexW2519242424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.